Objectives Exploring the use of statins as anticancer agents and exploiting different drug delivery systems in targeting these molecules to cancerous sites. Literature review was performed to investigate the use of statins in cancer treatment in one hand, and the different pharmaceutical approaches to deliver and target these drugs to their site of action. Key findings Statins were used for decades as antihypercholestrolemic drugs but recently have been proven potential for broad anticancer activities. The incorporation of statins in nanoparticulate drug delivery systems not only augmented the cytotoxicity of statins but also overcame the resistance of cancerous cells against the traditional chemotherapeutic agents. Statins-loaded nanoparticles could be easily tampered to target the cancerous cells and consequently minimal drug amount could be utilized. Summary This review reconnoitered the different endeavors to incorporate statins in various nanoparticles and summarized the successful effects in targeting cancerous cells and reducing their proliferation without the side effects of commonly used chemotherapeutic agents.
Introduction
Cancer is commonly defined as an uncontrollable growth of cells owing to mutations that occurs in the genes controlling the proliferation of cells. To date, chemotherapy is the most powerful therapeutic tool against progressed, disseminated cancers. However, this management was usually suppressed because of the onset of adverse effects and the resistance against wide range of anticancer agents. The latter phenomenon is known as multidrug resistance (MDR) that occurrs in tumours at the diagnostic stage or during relapses and metastatic spreading. [1] Anthracyclines, particularly doxorubicin, were the first choice for the treatment of many haematological and solid tumours despite their cardiotoxicity. [2] Being a substrate to ATP-binding cassette (ABC) membrane pumps such as P-glycoproteins (Pgp) and multidrug resistance-related proteins (MRPs), doxorubicins are expelled out of the cancerous cells that overexpress these transporters and hence noticeable decrease in intracellular drug concentration was observed with subsequent side effects. [1] From these observations, concomitant administration of inhibitors to these proteins was a must to achieve intracellular drug concentration that lead to therapeutic effects. Unfortunately, these compounds also showed high toxicity with poor specificity. [3] On the other hand, statins, in particular, were found to elicit inhibitory effect on Pgp and MDR because this class was proven to cause nitration of critical tyrosines of Pgp which led to obvious decrease in the pump activity. [4, 5] Statins are mainly cholesterol-lowering agents. They are commonly used in the treatment of hypercholesterolemia, dyslipidemia and coronary heart diseases. All statins possess a 3-hydroxy-3-methylglutaryl (HMG)-like moiety that has high affinity to HMG-CoA reductase so sterically block this enzyme thereby inhibiting the production of mevalonate, the first step in the cholesterol biosynthesis. [6] Moreover, statins are used in the treatment of aortic aneurysms, [7] inflammatory colitis, [8, 9] chronic renal disease, [10, 11] nasal polyp disease [12] and chronic lymphocytic leukaemia. [13] [14] [15] [16] Statins are classified based on their hydrophilic/lipophilic properties. Hydrophilic statins, like pravastatin (PRV), are unable to penetrate membrane lipid bilayers. In contrast, the lipophilic statins like lovastatin (LV), simvastatin (SV), atorvastatin (ATV) and fluvastatin (FV) (Figure 1 ) can directly cross cell membranes and, in addition to their cholesterol-lowering hepatic effects, exert pleotropic effects in many extrahepatic tissues. [17] Nowadays, there is an emerging interest in the use of statins as anticancer agents owing to their pleiotropic effect on various cells and tissues. High levels of mevalonate production were documented in various types of malignancies such as breast cancer, [18] leukaemia, lymphoma [19, 20] and prostate carcinoma cells. [21] Hence, as statins were proven to block mevalonate pathway by inhibiting HMG-CoA reductase, this would result in reduced levels of mevalonate and its downstream products which were isoprenoids intermediates. These intermediates are farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These two intermediates were responsible for prenylation of Rho proteins. Depletion of the latter intermediates inhibits lipid attachment sites for activated Ras, Rac, and Rho family members. [22] These proteins offered a great potential for cancer formation and its progression such as membrane integrity, cell signalling, cell cycle progression, immune/ inflammatory reactions, stromal-epithelial cell interactions, endogenous energy metabolism, oxidative stress, and intracellular vitamin and steroid content. [23, 24] Any changes caused in these processes would lead to inhibition of tumour initiation, growth and metastasis. Consequently, statins represented an attracting chemotherapeutic agent in cancer therapies. [25] [26] [27] Lipophilic statins such as simvastatin [28] and lovastatin [29] exerted anticancer effect as they could permeate cell membrane. [30, 31] To this end, the antitumour activity of statins were boosted greatly by using tumour-targeted delivery systems where intra-tumour drug concentrations were increased. [32] So in this current context, researchers converged on the treatment of cancer using statins formulated in different drug delivery systems using nanotechnology. Nanotechnology in drug delivery has emerged in the early 2000's. It was an escalating or rising technique for preparing functional systems at submicron levels. Nanocarriers are within the range of 10-400 nm expediting the encapsulation of drugs and delivering them through biological membranes. [33] These carriers offer great advantages than traditional systems in protecting drugs against degradation and enhancing sustained release effect and thereby the frequent administration of drug is prohibited. [34, 35] Moreover, they can be selected or tailored to entrap both hydrophilic and lipophilic drugs. These aforementioned properties of nanocarriers represent promising techniques to treat cancerous cells by encapsulating anticancer drugs and minimizing their wide range of toxicities. In the current work, we are reviewing and highlighting the different approaches of the delivery and targeting of statins to cancerous cells and tumours using nanocarriers or nanosystems.
Passive Targeting
The delivery of anticancer drugs to tumour cells is enhanced by the enhanced permeability and retention (EPR) effect. EPR depends on the presence of fenestrations in the imperfect tumour blood vessels and to the poor lymphatic drainage in the tissue. The nanoformulations containing anticancer drugs are preferentially accumulated in tumour cells depending on EPR too. [36] Furthermore, the nanoparticles (NPs) characteristics affect greatly tumour penetration. Nanoparticles should be less than the pore size of the fenestrations. Sizes 30-100 nm penetrate preferentially to the hyperpermeable tumour as shown in Figure 2 . [37] The particle size also plays a vital role in the tumour cells uptake. Huo et al. [38] showed that the NPs accumulated in the tumour cells depending on their sizes where the 50-nm particles more accumulated in the MCF-7 cell lines than the 100-nm counterparts.
Moreover, Figure 2 shows that the NPs charge plays a crucial role in tumour penetration. Positive charges were proven to enhance the NPs interaction with the tumour vasculature favouring their diffusion deep into the tumour cells and eliminating the systemic circulation. [39, 40] Researches scrutinised that the zeta potential above certain threshold viz. +10 mV or À30 mV enhances the tumour accumulation revoking its diffusion out of tumour cells. [41] [42] [43] The shape of the NPs also exert a beneficial effect in tumour penetration as it affects the blood exposure by modulating the interactions with mononuclear phagocytic system (MPS). [44] [45] [46] [47] Elongated NPs preferentially accumulated in the tumour through their pores. [48] while nanorods were shown to extravasate to the interstitium four times faster and to diffuse deeper in the tumour than nanospheres. [49] Another parameter that enhances the EPR is the circulation time of NPs in the blood stream. Prolonged circulation of NPs enhances the extravasation in the tumour interstitium. For example, NPs decorated with PEG of high molecular weight (Mw) highly accumulates in tumour tissues because they bypass the glomerular filteration and hence the renal elimination of these NPs are abolished. [50, 51] A plethora of studies based on the combination of NPs and statins in passive targeting to the solid tumours is found in the literature.
Liposomes
Liposomes are spherical self-assembled phospholipid vesicles. Liposomes incorporate an aqueous phase surrounded by phospholipid bilayer. [52] Owing to its chemical composition, liposomes represent an effective tool for delivery of various active agents, among which are the water-soluble and the lipid-soluble drugs, nutraceuticals and foodderived bioactives. Based on the number and size of phospholipid bilayer, liposomes are classified into unilamellar vesicles (UV) or multilamellar vesicles (MLV). Unilmaellar vesicles may be either small (SUV) or large unilamellar vesicles (LUV). Alupei (2015) and coworkers [32] got benefit from both antitumour activity of statins and long circulating property of liposomes to ameliorate the pattern of cancer management, where the antitumour activity was mainly based on the reduction of the tumour-associated macrophages mediated oxidative stress as well as of the production of the hypoxia-inducible factor 1 a (HIF-1 a) in tumours. Long circulating liposomes (LCL) possessed the ability to extravasate through the hyperpermeable vasculature of the tumours and to concentrate in the malignant tissue owing to EPR property of the tumour vasculature. [53] [54] [55] Furthermore, it was formerly confirmed that LCLs have natural tropism for tumour-associated macrophages (TAMs). [56, 57] TAMs enhances the growth of tumour by stimulating the nitric oxide (NO) production that is reversible inhibitor of catalase enzyme. [58, 59] Additionally, statins were proven to exert an inhibitory effect on NO synthesis in macrophage thus its antitumour activity. [60, 61] Banciu and collaborators (2008) [56] performed a comparative study for the effect of LCL-SV and free SV on B16. F10 melanoma bearing mice. LCL-SV exerted noticeable decrease in both rate and volume of the tumour growth compared with those received free SV. Compared with the control group, the growth of the tumour was greatly curtailed by 85% as represented in Table 1 . They declared the importance of the presence of TAMs in the antitumour activity of LCL-SV. The SV-loaded nanocarriers accumulated in the endosomal/lysosomal compartments of TAMs [57] resulting in greater antioxidant activity on B16.F10 melanoma. It is claimed that the inhibition of metastasis of the B16.F10 melanoma and the suppression of the survival capacity of tumours were achieved via LCL-SIM as it strongly inhibited the production of the hypoxia-inducible factor HIF-1a that was necessary for progression and invasion of B16.F10 melanoma. [62] [63] [64] Maria Coimbra (2010) and coworkers found that PRV encapsulated in LCL targeting murine B16F10-melanoma reduced the tumour growth by a value approaching 70% compared with the free PRV solution as represented in Table 1 . [65] Chitosan NPs Polymeric NPs had the ability to enhance the drug loading capacity, stability and the therapeutic activity of the anticancer drugs. [66] Natural biocompatible polymeric NPs possessed biological properties that appealed the attention to entrap chemotherapeutic agents [67] and accumulated in the tumour tissue owing to EPR effect. [68] Chitosan nanoparticles are promising drug delivery systems owing to their low toxicity, low immunogenicity, biocompatibility and biodegradability. [69] There is an arousing interest for the use of chitosan NPs (CSNPs) as anticancer carrier. [70] Their anticancer activity was attributed to their interference in metabolism of cancer cells and hence inhibiting their growth, [71] disrupting the membrane of the tumour and inducing apoptosis. [72] They represent an efficient tool to deliver anticancer drugs to cancerous cells owing to their mucoadhesive properties to the tumour membrane. [73] Positively charged CSNPs having size less than 200 nm exhibited higher anticancer effects than other NPs [74] as they target the leaky vasculature of the tumour by the well-known EPR phenomenon. [70] Badran et al. utilized a hydrophilic statin such as pravastatin (PRV) as it had boosted antitumour activity against Simvastatin Liposomes Active HT29 -- [149] Pravastatin Chitosan nanogel Active HepG2 -28 [77] PLGA, Poly (D,L-lactide-co-glycolide).
hapatocellular carcinoma compared with other statins. [75, 76] PRV exhibited selective antitumour activity against hepatocellular carcinoma (HCC) lines [77] [78] [79] as shown in Table 1 . PRV/CSNPs augmented the cytotoxicity of each of pravastatin solution and plain CSNPs against HepG2 cells by 35% death of cell lines compared with 9.6%, 17.4% and 12% for CS solution, plain CSNPs and PRV solution, respectively. This could be interpreted by the adsorption of PRV/CSNP on the tumour membrane enhancing more drug influx inside the cancerous cells. [70] Moreover, Yokoi et al. [80] observed that the alteration of pH of the tumour microenvironment together with EPR effect allowed more PRV/CSNP uptake into cancerous cells. Mekhail et al. [81] encapsulated atorvastatin (ATV) in amphiphilic copolymers via polymeric micellization to target human breast adenocarcinoma cell line (MCF 7) and human colon carcinoma cell line (HCT 116). Amphiphilic copolymers were obtained by chemically grafting cationic chitosan with hydrophobic moieties. These amphiphilic copolymers of stearyl chitosan (SC) and sulfated stearyl chitosan (S-SC) could self-assemble in blood stream exhibiting prolonged circulation without being detected by macrophages, additionally, it would accumulate at the leaky vasculature throughout EPR effect. Polymeric micelles were proven highly successful in solid tumour targeting than NPs, liposomes and lipid-based drug delivery systems especially when using biocompatible and biodegradable polymers. [82] ATV-loaded micelles boosted the cytotoxicity of free drug where IC50 values after 72 h incubation with MCF 7 and HCT 116 were 3.7 AE 0.2 lg/ml and 3.4 AE 0.2 lg/ml, respectively, compared with IC50 10.4 AE 0.5 and 9.4 AE 0.8 for free drug for MCF 7 and HCT 116, respectively, as given in Table 1 . Furthermore, the unloaded polymeric micelles were safe on both types of cells as no cytotoxicity was detected indicating that these micelles were promising candidates for drug delivery. The cytotoxicity of the loaded systems was attributed to the facilitated adhesion of the nanoparticles to the cell membrane because of the polysaccharide nature of chitosan followed by adsorptive endocytosis triggered by non-specific interactions between the nanoparticles and cell membranes. [83] Moreover, electrostatic interaction between the negatively charged polymeric micelles and the few cationic sites on the cell membrane would favour endocytosis. [84] Stearyl chitosan enhanced the fluidity of the cell membrane with better drug accumulation inside the cells offering higher cytotoxicity of loaded micelles than free drug solution. [81] Lipid nanocapsules Lipid nanocapsules (LNC) represent smart drug delivery systems as their structure compromise the properties of both polymeric NPs and liposomes. [85] They consist of less toxic biomimetic materials with sizes below endothelium fenestrations. Moreover, the incorporation of a pegylated surfactant in LNCs structure; solutol, imparts stealth properties to these interesting nanoparticles. Consequently, targeting the tumour cells with lower side effects and bypassing uptake by mononuclear phagocytic systems are attainable using these unique nanocarrriers. Passive targeting of breast cancer was recently accomplished utilizing SV-loaded lipid nanocapsules (SV-LNC). [86] SV-LNC exhibited stealth properties owing to the incorporation of the pegylated surfactant and consequentely prolonged circulation times were achieved. The encapsulation of SV in LNC boosted the drug cytotoxicity. SV-LNC exerted a cytotoxic effect on MCF-7 cell lines with IC50 equals to 1.4 AE 0.2 lg/ml, compared with pure SV (IC50 = 5.4 AE 0.6 lg/ml), as given in Table 1 , this showed that LNC augmented the cytotoxicity of SV. This could be interpreted by Laine et al. [87] and Paillard et al. [88] where LNC were efficiently uptaken by glioma cells through endocytic pathway. Moreover, solutol was proven to block P-gp-related drug efflux which is frequently involved in the resistance of the tumour cells to anticancer agents. [89] Microemulsions and statins Ishak and Osman (2015) enhanced the delivery of poorly water-soluble anticancer drug atorvastatin (ATV) to the lungs via microemulsions. [90] The use of microemulsions and self-microemulsifying drug delivery system overcame the solubility problem of atorvastatin. [91] The preparation of microemulsions (ME) necessitates the use of considerable amount of surfactants (SAA) and co-surfactants [92, 93] which usually lead to toxicity risks. [94] Usually, lecithin which is considered a biological, nontoxic surface active agent and is one of the inherent components of the lung was is used. [95, 96] D-a-Tocopheryl polyethylene glycol 1000 succinate (TPGS), generally recognized as safe (GRAS), was used as an alternative to the highly hydrophobic lecithin in the preparation of atorvastatin microemulsions. [90] The incorporation of TPGS in developing the ME augmented the cytotoxicity of ATV where the IC50 of AVT solution and AVT-ME on A549 lung cancer cells were 44 lg/ml and 11.58 lg/ml respectively as shown in Table 1 . This could be ascribed to the reversal of the multidrug resistant (MDR) effect of the cancer cells [97] as well as to the P-gp inhibitory effect of AVT being a substrate for this transporter. [98] Such a combination showed a synergistic antitumour activity. [99] [100] [101] 
Lipid nanoemulsions
Lipid nanosized emulsions or nanoemulsions (NE) are oil in water dispersions with an oil droplet size of about 200 nm. [102] A combination treatment of simvastatin and Tocotrienol rich fraction (TRF) of vitamin E exerted an antiproliferative effect against human MCF-7 and MDA-MB-231 mammary adenocarcinoma cell lines. [103] It was previously shown that TRF exerted also antiproliferative effect against the highly malignant murine mammary tumour cells [104] which was augmented by the addition of simvastatin. The cytotoxicity of TRF/SV in parenteral lipid nanoemulsion was evaluated on both MCF-7 and MDA-MB-231 cells. MDA cell lines were more sensitive to TRF than MCF since MDA showed greater overexpression of the epidermal growth factor receptor (EGFR) and protein kinase C (PKC) [105, 106] that represented the two main targets for TRF. [107] The date in Table 1 reveals that TRF/SV lipid nanoemulsion scored IC50 (lM) of = 10.3 and 4.9 on MCF7 and MDA 231, respectively compared with TRF nanoemulsion alone (IC50 = 14 and 7 on MCF7 and MDA 231 respectively) and SV solution alone (IC50 = 19 and 8 on MCF and MDA 231 respectively). These findings further confirmed the substantial anticancer activity of statins.
PLGA NPs and statins
PLGA stands for Poly (D,L-lactide-co-glycolide) and is one of the frequently used biodegradable polymers in drug delivery systems for cancer therapy. [108] [109] [110] [111] Linear PLGA possessed several drawbacks that led to its limited use such as high hydrophobicity, limited entrapment and low loading properties. [112, 113] Thus, the branched, dendritic and star-shaped ones appealed the researches for use owing to their enhanced physical, chemical and biological properties. [114] [115] [116] Wu and coworkers (2015) utilized the steroidal nucleus of cholic acid (CA) to initiate the formation of star-shaped CA-PLGA polymers. [117] SV-loaded star-shaped CA-PLGA significantly reduced the cell viability of MDA-MB-231. From Table 1 , it could be deduced that simvastatin-loaded star-shaped CA-PLGA caused 65.35% reduction in different cell lines (MDA-MB-231 and MDA-MB-468) compared with 58.99% and 52.66% for SV solution and SV-loaded linear PLGA NPs, respectively, for 24 h. After 48 h incubation, the reduction in cell viability was increased especially for SV-loaded star-shaped CA-PLGA NPs giving evidence not only of drug with enhanced cytotoxicity but also that a sustained drug release could be achieved. The enhanced cytotoxicity of SV-loaded CA-PLGA was further confirmed by the reduction in the tumour growth rate in BALB/c nude mice by 74.50%, 60.27% and 48.74% for loaded starshaped CA-PLGA NP formulation, loaded PLGA NPs and SV respectively. These observations proved that SV-loaded CA-PLGA NPs offered sustained and controlled release of drug enhancing the passive targeting of the tumour based on EPR effect.
Active Targeting
This type of drug targeting is also known as ligand-mediated targeting. It depends on the affinity of ligands on the surface of the NPs to target certain receptors and thus the NPs are uptaken and retained by the disease cells. [36] Actively targeted NPs depend on the enhanced permeation and retention effect (EPR effect) to reach their target moiety, hence these smart systems should exhibit prolonged circulation time as well. [118, 119] Actively targeted NPs should have optimum size comparable to fenestrations of the tumour. [36] The hydrophilicity of the final system should be taken in consideration i.e. PEG (hydrophilic moiety) of minimal concentration maximizes the blood circulation preventing the adsorption to opsonins while using long and dense PEG chains hinder the NP from reaching the target. [120, 121] Selection of the ligands depends on the overexpression of surface molecules or the receptors in the diseased organs or cells. [122] [123] [124] [125] Active targeting aims to introduce the ligand in the proximity of the NPs and consequently the affinity between the ligand and the targeted receptor is increased. [123, 126, 127] Active targeting process was found to be affected by many parameters such as; NP architecture, the ligand conjugation chemistry, the type of the ligand, administration route and the non-specific binding of the proteins after NPs administered. [44, 128] Furthermore, a variety of physicochemical properties related to ligand carrying platforms influenced the fate of active targeting as ligand density [129] ; NP size [130] and the type of the ligand. [131] It was reported that the increased ligand density resulted in multiple interaction between NPs and receptors, clustering NPs around the cell membrane, this wraps the cell membrane and hence internalization and cellular uptake of NPs are improved. [121, 129, 132] Figure 2 demonstrates the different types of ligands that could be utilized such as antibodies (Ab) and their fragments, proteins, peptides, nucleic acids, sugars, lipids and small molecules such as vitamins. [133] [134] [135] Ab-targeted NPs faced many drawbacks as Ab represented high molecular weight with large hydrodynamic radius resulting in hindering the receptor conjugation. [136, 137] Being attached to Ab, this enhanced actively designed NPs recognition by the immune system and hence their elimination from systemic circulation. [138, 139] This was overcome by using fragments of the Ab and not monomers nor dimers as they have bulky structures. [123, 140] Hence, this was solved by removing the Fc fragment of the antibodies. [141] Also, protein ligands can be incorporated in NPs system. Unfortunately, they exhibited some limitations as Ab; the bulky nature and recognition by the immune system. They are subjected to metabolism and clearance as well. [142, 143] A commonly used peptide as ligand was RGD (arginineglycine-aspartic acid) peptide family, which can bind strongly to avb3 integrin receptors. [124, 125] Nucleic acid-based aptamers (Apts) are another types of ligands. Apts are short single-stranded oligonucleotides, such as DNA, RNA or modified nucleic acids (xeno-nucleic acids XNA). [144, 145] They possess negative charges and degrade by nucleases which affect their circulation time. Apts should not be available at densities greater than 5%, if so they will be recognized and captured by the macrophage phagocytic system. [129] In most cases, NPs were covalently bonded to the ligand, however, physical adsorption can be utilized effectively. [146] For chemical conjugation, bifunctional linkers were used to couple the ligand with polymers or NPs. [44] For non-covalent method, streptavidin-biotin interactions were preferred to synthetic conjugation. [146] Biotin is commonly used owing to its small size so not affect the function of the ligand. [147] This design was commonly and preferentially used for antibodies, peptides and aptamers. [148] Liposomes Kopecka and coworkers (2011) utilized the advantages of both statins and liposomal technology to deliver doxorubicin to cancerous cells with minimal side effects. [149] Statins mainly inhibit HMG-CoA reductase enzyme (HMGCR) consequently its downstream products as previously mentioned. From this aspect, statins exert pleiotropic effect on cancerous cells where tumours with high levels of multidrug resistant (MDR) contained high amounts of cholesterol in their plasma membrane which were essential to maintain Pgp activity. [150] It was observed that there was a direct correlation between the cholesterol content in the plasma membrane and the ATPase activity of Pgp [151, 152] together with their overexpression in the tumour cells. [153, 154] Thanks to statins that inhibit HMGCR, the reduction in the amount of cholesterol will force the cells to increase low density lipoproteins (LDL) receptor synthesis. [155] Coupling to the liposomes, LDL mimicking lipid particles would boost this benefit. A short peptide from apoB100 protein, that contains the LDL receptor-binding site, will enhance its endocytosis. [156] Co administration of statins (SV) with apoB100-conjugated liposomal doxorubicin ("apo-Lipodox") was found to reduce the level of cholesterol and consequently decrease the activity of P-gp that was associated with the elevation of the expression of LDL receptor, resulting in greater accumulation of doxorubicin in the Human colon cancer HT29 cells.
Chitosan nanogels
Nanogels are considered smart drug delivery systems that are biocompatible, biodegradable and absorption enhancers. [69] Chitosan was employed in this nanotechnology owing to its several beneficial effects such as its hypocholestrolemic, anticancer and others effects. [157, 158] Harisa et al. combined both chitosan (CS) nanogels and erythrocytes as drug delivery systems. [77, 159, 160] The addition of erythrocytes (ER) offer great advantages as being biocompatible, biodegradable, having long life span and the presence of several preparation methods for its enhanced drug loading. [161] Targeting the reticuloendothelial systems was possible with drug loaded erythrocytes. [162] Harisa et al. [77] focused on the selective antitumour activity of PRV against hepatocellular carcinoma. They prepared erythrocytes loaded PRV-chitosan nanogels (PR-CNG-ER). This system had a pronounced antitumour activity against HepG2 cells where PR-CNG-ER decreased in cell viability by 28% compared with PR-ER and CNS-ER where their reduction in cell viability was 18% and 13% respectively. Shen et al. [163] demonstrated the ability of CS to inhibit proliferation of HepG2 cells in addition to its cationic property that exerts antitumour effect by promoting cellular uptake and drug release inside cancerous cells. [70, 158] CS can disturb the cell membrane interfering in cell metabolism and induce apoptosis inhibiting cell growth. [70] Although the presence of targeting ligand might grant better clinical efficacy, yet, other risks are present that are associated with the complex chemistry, manufacturing and control procedures of the ligands-decorated nanocarriers upon reaching commercialization. However, researches made aiming active cancer targeting are numerous and diverse. The design of actively targeted NPs is sophisticated as the efficacy of the system was controlled by many parameters as previously described and no currently commercially available products are found to date. It was also observed that the development of the targeted drug delivery system is more costly than the non-targeted NPs. [164] Furthermore, there are increased discovered difficulties in the preparation and manufacture of actively targeted NPs at the industrial level. Targeting the overexpressed proteins might lead to non-specific distribution and off target toxicities. [36] Besides, detecting the impact of active targeting in humans was proven as a hard task. Further studies such as accurate phenotyping techniques are demanded. [165] 
Conclusion
In this context, we pursued the effect of statins as anticancer agents in various drug delivery systems. NPs loaded with statins could be utilized as successful and novel drug delivery systems for the treatment of various types of cancer together with limited side effects owing to their efficiency in targeting the cancerous cells and inhibiting their growth and proliferation. These systems such as the lipid nanocapsules offered merits not only in their biological effects on cell lines but also in their physical characterization and stability. SV-loaded lipid nanocapsules and star-shaped CA-PLGA could appeal the attention for their pronounced cytotoxicity. These systems might be promising medicines for the management of different types of tumours but this requires further preclinical and clinical studies on their targeting ability to the cancerous cells. Furthermore, more studies are required on the possibility of large scale industrial production of statins-loaded NPs.
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